Redx Pharma plc Reversible BTK poster at ASH meeting

TIDMREDX

Redx Pharma plc

06 December 2016

6 December 2016

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company" or "the Group")

Pre-clinical profile of reversible BTK inhibitor RXC005 presented at ASH 2016

Redx, the drug development company, is pleased to announce that it has presented the pre-clinical profile of its reversible Bruton's tyrosine kinase (BTK) inhibitor RXC005 at the 58(th) American Society of Hematology (ASH) Annual Meeting in San Diego, California, United States, on 5 December 2016.

Redx's development candidate RXC005 is a novel, potent and selective, reversible BTK inhibitor with efficacy and equivalent potency against wild-type and cysteine-481 (C481) mutated BTK. First generation BTK inhibitors, such as ibrutinib and acalabrutinib, specifically target C481 within BTK and mutations at this site interfere with covalent drug binding. Several mutations have been reported and linked to cases of resistance that have emerged in patients with chronic lymphocytic leukaemia (CLL) progression following treatment with ibrutinib. Redx's reversible BTK inhibitor RXC005 aims to overcome this resistance mechanism by targeting both wild type and C481-mutated BTK.

The Company is progressing studies to prepare the RXC005 program for first-in-human clinical trials. The aim is to commence these trials late 2017.

Dr Neil Murray, CEO of Redx, said:

"We're delighted to have presented the compelling pre-clinical profile of our reversible BTK inhibitor RXC005 at the ASH 2016 meeting in San Diego.

"RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients by tackling the growing resistance to ibrutinib treatment. We aim to initiate first-in-human clinical studies for RXC005 late 2017."

The ASH Poster for RXC005 (poster #4399) is available on the Investor section of the Company's website: www.redxpharma.com/investors.html

For further information, please contact:

 
Redx Pharma Plc 
Neil Murray, Chief Executive                 T: +44 1625 
                                                 469 900 
Karl Hård, Head of Investor Relations   T: +44 7491 
 &                                               651 406 
 Corporate Communications 
 
  Cantor Fitzgerald Europe (Nomad & Broker)    T: +44 20 
                                               7894 7000 
Phil Davies/ Michael Reynolds 
 

About Redx Pharma Plc

Company website: Redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhoea, bone tumours, skin, brain, breast, pancreatic and blood cancers.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUVRURNSAURUA

(END) Dow Jones Newswires

December 06, 2016 02:01 ET (07:01 GMT)